Glucose-induced hyperproliferation of cultured rat aortic smooth muscle cells through polyol pathway hyperactivity

J. Nakamura, Y. Kasuya, Y. Hamada, E. Nakashima, Keiji Naruse, Y. Yasuda, K. Kato, N. Hotta

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

Aims/hypothesis. The protein kinase C (PKC), platelet-derived growth factor (PDGF) and polyol pathway play important parts in the hyperproliferation of smooth muscle cells, a characteristic feature of diabetic macroangiopathy. The precise mechanism, however, remains unclear. This study investigated the relation between polyol pathway, protein kinase C and platelet-derived growth factor in the development of diabetic macroangiopathy. Methods. Smooth muscle cells were cultured with 5.5 or 20 mmol/1 glucose with or without an aldose reductase inhibitor, epalrestat, or a PKC-β specific inhibitor, LY333 531. Protein kinase C activities, the expression of PKC-βII isoform and PDGF-β receptor protein, free cytosolic NAD+:NADH ratio, the contents of reduced glutathione, and proliferation activities were measured. Results. Smooth muscle cells cultured with 20 mmol/1 glucose showed statistically significant increases in protein kinase C activities, the expression of PKCβII isoform and PDGF-β receptor protein, and proliferation activities, compared with smooth muscle cells cultured with 5.5 mmol/1 glucose. Although epalrestat and LY333 531 inhibited protein kinase C activation induced by glucose to the same degree, the effects of epalrestat on proliferation activities and expression of the PDGF-β receptor were more prominent than those of LY333531. Epalrestat improved the glucose-induced decrease in free cytosolic NAD+:NADH ratio and reduced glutathione content, but LY333 531 did not. The increased expression of membranous PKC-βII isoform was normalized by epalrestat. Conclusion/interpretation. These observations suggest that polyol pathway hyperactivity contributes to the development of diabetic macroangiopathy through protein kinase C, PDGF-β receptor, and oxidative stress, and that an aldose reductase inhibitor has a therapeutic value for this complication.

Original languageEnglish
Pages (from-to)480-487
Number of pages8
JournalDiabetologia
Volume44
Issue number4
DOIs
Publication statusPublished - 2001
Externally publishedYes

Fingerprint

Protein Kinase C
Smooth Muscle Myocytes
Glucose
Platelet-Derived Growth Factor Receptors
NAD
Aldehyde Reductase
Protein Isoforms
Platelet-Derived Growth Factor
ruboxistaurin
Glutathione
polyol
Proteins
Oxidative Stress
epalrestat

Keywords

  • Aldose reductase inhibitor
  • Diabetic macroangiopathy
  • Oxidative stress
  • Platelet-derived growth factor
  • Protein kinase C

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Glucose-induced hyperproliferation of cultured rat aortic smooth muscle cells through polyol pathway hyperactivity. / Nakamura, J.; Kasuya, Y.; Hamada, Y.; Nakashima, E.; Naruse, Keiji; Yasuda, Y.; Kato, K.; Hotta, N.

In: Diabetologia, Vol. 44, No. 4, 2001, p. 480-487.

Research output: Contribution to journalArticle

Nakamura, J, Kasuya, Y, Hamada, Y, Nakashima, E, Naruse, K, Yasuda, Y, Kato, K & Hotta, N 2001, 'Glucose-induced hyperproliferation of cultured rat aortic smooth muscle cells through polyol pathway hyperactivity', Diabetologia, vol. 44, no. 4, pp. 480-487. https://doi.org/10.1007/s001250051646
Nakamura, J. ; Kasuya, Y. ; Hamada, Y. ; Nakashima, E. ; Naruse, Keiji ; Yasuda, Y. ; Kato, K. ; Hotta, N. / Glucose-induced hyperproliferation of cultured rat aortic smooth muscle cells through polyol pathway hyperactivity. In: Diabetologia. 2001 ; Vol. 44, No. 4. pp. 480-487.
@article{f4e8c8d3b2e14d1d96e811435390f3b4,
title = "Glucose-induced hyperproliferation of cultured rat aortic smooth muscle cells through polyol pathway hyperactivity",
abstract = "Aims/hypothesis. The protein kinase C (PKC), platelet-derived growth factor (PDGF) and polyol pathway play important parts in the hyperproliferation of smooth muscle cells, a characteristic feature of diabetic macroangiopathy. The precise mechanism, however, remains unclear. This study investigated the relation between polyol pathway, protein kinase C and platelet-derived growth factor in the development of diabetic macroangiopathy. Methods. Smooth muscle cells were cultured with 5.5 or 20 mmol/1 glucose with or without an aldose reductase inhibitor, epalrestat, or a PKC-β specific inhibitor, LY333 531. Protein kinase C activities, the expression of PKC-βII isoform and PDGF-β receptor protein, free cytosolic NAD+:NADH ratio, the contents of reduced glutathione, and proliferation activities were measured. Results. Smooth muscle cells cultured with 20 mmol/1 glucose showed statistically significant increases in protein kinase C activities, the expression of PKCβII isoform and PDGF-β receptor protein, and proliferation activities, compared with smooth muscle cells cultured with 5.5 mmol/1 glucose. Although epalrestat and LY333 531 inhibited protein kinase C activation induced by glucose to the same degree, the effects of epalrestat on proliferation activities and expression of the PDGF-β receptor were more prominent than those of LY333531. Epalrestat improved the glucose-induced decrease in free cytosolic NAD+:NADH ratio and reduced glutathione content, but LY333 531 did not. The increased expression of membranous PKC-βII isoform was normalized by epalrestat. Conclusion/interpretation. These observations suggest that polyol pathway hyperactivity contributes to the development of diabetic macroangiopathy through protein kinase C, PDGF-β receptor, and oxidative stress, and that an aldose reductase inhibitor has a therapeutic value for this complication.",
keywords = "Aldose reductase inhibitor, Diabetic macroangiopathy, Oxidative stress, Platelet-derived growth factor, Protein kinase C",
author = "J. Nakamura and Y. Kasuya and Y. Hamada and E. Nakashima and Keiji Naruse and Y. Yasuda and K. Kato and N. Hotta",
year = "2001",
doi = "10.1007/s001250051646",
language = "English",
volume = "44",
pages = "480--487",
journal = "Diabetologia",
issn = "0012-186X",
publisher = "Springer Verlag",
number = "4",

}

TY - JOUR

T1 - Glucose-induced hyperproliferation of cultured rat aortic smooth muscle cells through polyol pathway hyperactivity

AU - Nakamura, J.

AU - Kasuya, Y.

AU - Hamada, Y.

AU - Nakashima, E.

AU - Naruse, Keiji

AU - Yasuda, Y.

AU - Kato, K.

AU - Hotta, N.

PY - 2001

Y1 - 2001

N2 - Aims/hypothesis. The protein kinase C (PKC), platelet-derived growth factor (PDGF) and polyol pathway play important parts in the hyperproliferation of smooth muscle cells, a characteristic feature of diabetic macroangiopathy. The precise mechanism, however, remains unclear. This study investigated the relation between polyol pathway, protein kinase C and platelet-derived growth factor in the development of diabetic macroangiopathy. Methods. Smooth muscle cells were cultured with 5.5 or 20 mmol/1 glucose with or without an aldose reductase inhibitor, epalrestat, or a PKC-β specific inhibitor, LY333 531. Protein kinase C activities, the expression of PKC-βII isoform and PDGF-β receptor protein, free cytosolic NAD+:NADH ratio, the contents of reduced glutathione, and proliferation activities were measured. Results. Smooth muscle cells cultured with 20 mmol/1 glucose showed statistically significant increases in protein kinase C activities, the expression of PKCβII isoform and PDGF-β receptor protein, and proliferation activities, compared with smooth muscle cells cultured with 5.5 mmol/1 glucose. Although epalrestat and LY333 531 inhibited protein kinase C activation induced by glucose to the same degree, the effects of epalrestat on proliferation activities and expression of the PDGF-β receptor were more prominent than those of LY333531. Epalrestat improved the glucose-induced decrease in free cytosolic NAD+:NADH ratio and reduced glutathione content, but LY333 531 did not. The increased expression of membranous PKC-βII isoform was normalized by epalrestat. Conclusion/interpretation. These observations suggest that polyol pathway hyperactivity contributes to the development of diabetic macroangiopathy through protein kinase C, PDGF-β receptor, and oxidative stress, and that an aldose reductase inhibitor has a therapeutic value for this complication.

AB - Aims/hypothesis. The protein kinase C (PKC), platelet-derived growth factor (PDGF) and polyol pathway play important parts in the hyperproliferation of smooth muscle cells, a characteristic feature of diabetic macroangiopathy. The precise mechanism, however, remains unclear. This study investigated the relation between polyol pathway, protein kinase C and platelet-derived growth factor in the development of diabetic macroangiopathy. Methods. Smooth muscle cells were cultured with 5.5 or 20 mmol/1 glucose with or without an aldose reductase inhibitor, epalrestat, or a PKC-β specific inhibitor, LY333 531. Protein kinase C activities, the expression of PKC-βII isoform and PDGF-β receptor protein, free cytosolic NAD+:NADH ratio, the contents of reduced glutathione, and proliferation activities were measured. Results. Smooth muscle cells cultured with 20 mmol/1 glucose showed statistically significant increases in protein kinase C activities, the expression of PKCβII isoform and PDGF-β receptor protein, and proliferation activities, compared with smooth muscle cells cultured with 5.5 mmol/1 glucose. Although epalrestat and LY333 531 inhibited protein kinase C activation induced by glucose to the same degree, the effects of epalrestat on proliferation activities and expression of the PDGF-β receptor were more prominent than those of LY333531. Epalrestat improved the glucose-induced decrease in free cytosolic NAD+:NADH ratio and reduced glutathione content, but LY333 531 did not. The increased expression of membranous PKC-βII isoform was normalized by epalrestat. Conclusion/interpretation. These observations suggest that polyol pathway hyperactivity contributes to the development of diabetic macroangiopathy through protein kinase C, PDGF-β receptor, and oxidative stress, and that an aldose reductase inhibitor has a therapeutic value for this complication.

KW - Aldose reductase inhibitor

KW - Diabetic macroangiopathy

KW - Oxidative stress

KW - Platelet-derived growth factor

KW - Protein kinase C

UR - http://www.scopus.com/inward/record.url?scp=0035062863&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035062863&partnerID=8YFLogxK

U2 - 10.1007/s001250051646

DO - 10.1007/s001250051646

M3 - Article

C2 - 11357479

AN - SCOPUS:0035062863

VL - 44

SP - 480

EP - 487

JO - Diabetologia

JF - Diabetologia

SN - 0012-186X

IS - 4

ER -